2,3,4,5-四氢-1H-3-苯并氮杂卓-7-胺 | 107393-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: 2,3,4,5-四氢-1H-3-苯并氮杂卓-7-胺
• 中文别名: 2,3,3',4,4',5,5',6-八氯联苯
• 英文名称: 2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamine
• 英文别名: 2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ylamine；7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine；2,3,4,5-tetrahydro-1H-3-benzazepin-7-amine；7-Amino-2,3,4,5-tetrahydro-1H-3-benzazepin
• CAS: 107393-73-7
• 化学式: C₁₀H₁₄N₂
• mdl: MFCD06410808
• 分子量: 162.235
• InChiKey: LOXPKSAIAHLVML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  2,3,4,5-四氢-1H-3-苯并氮杂卓-7-胺 在 氢溴酸 、 sodium nitrite 、 copper(I) bromide 作用下， 以 水 为溶剂， 生成 7-溴-2,3,4,5-四氢-1H-苯并[d]氮杂卓
  参考文献：
  名称：

  Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

  摘要：

  SCH 58261 is a reported adenosine A(2A) receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A(1) receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A(2A) receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A(2A) receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 mu M at physiological pH. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.069
• 作为产物：
  描述：

  7-硝基-2,3,4,5-四氢-1H-苯并[d]氮杂卓 在 10% Pd/C 、 氢气 作用下， 以 甲醇 为溶剂， 生成 2,3,4,5-四氢-1H-3-苯并氮杂卓-7-胺
  参考文献：
  名称：

  Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

  摘要：

  SCH 58261 is a reported adenosine A(2A) receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A(1) receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A(2A) receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A(2A) receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 mu M at physiological pH. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.069

文献信息

• [EN] SULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS<br/>[FR] DERIVES DE SULFONAMIDE UTILISES COMME AGENTS ANTIPSYCHOTIQUES
  申请人：GLAXO GROUP LTD

  公开号：WO2004031181A1

  公开（公告）日：2004-04-15

  The invention provides compounds of formula (I) wherein A and B represent the groups -(CH2)m- and -(CH2)n- respectively; R1 represents C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, -(CH2)pC3-6cycloalkyl, -(CH2)pOC3-6cycloalkyl, -COC1-6alkyl, -SO2C1-6alkyl, -SOC1-6alkyl, -S-C1-6alkyl, -CO2C1-6alkyl, -CO2NR4R5, -SO2NR4R5, -(CH2)pNR4R5, -(CH2)pNR4COR5, an optionally substituted aryl group, an optionally substituted heteroaryl group or an optionally substituted heterocyclyl group; R3 represents hydrogen or C1-6alkyl; Ar1 represents an optionally substituted heteroaryl group; Ar2 represents an optionally substituted phenyl or an optionally substituted heteroaryl group; Y represents a bond, -O-, -C1-6alkyl-, -CR6R7X-, -XCR6R7-, -NR8CO- or -CONR8-; X represents oxygen, sulfur, -SO- or -SO2-; R4 and R5 each independently represent hydrogen or C1-6alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R6 and R7 each independently represent hydrogen, C1-6alkyl or fluoro; R8 represents hydrogen or C1-6alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; or a pharmaceutically acceptable salt, solvate or pharmaceutically acceptable derivative thereof. The compounds are useful in therapy, in particular as antipsychotic agents.

  该发明提供了以下结构的化合物（I），其中A和B分别代表基团-(CH2)m-和-(CH2)n-；R1代表C1-6烷基；R2代表氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、-(CH2)pC3-6环烷基、-(CH2)pOC3-6环烷基、-COC1-6烷基、-SO2C1-6烷基、-SOC1-6烷基、-S-C1-6烷基、-CO2C1-6烷基、-CO2NR4R5、-SO2NR4R5、-(CH2)pNR4R5、-(CH2)pNR4COR5、一个可选择取代的芳基、一个可选择取代的杂芳基或一个可选择取代的杂环烷基；R3代表氢或C1-6烷基；Ar1代表一个可选择取代的杂芳基；Ar2代表一个可选择取代的苯基或一个可选择取代的杂芳基；Y代表一个键、-O-、-C1-6烷基-、-CR6R7X-、-XCR6R7-、-NR8CO-或-CONR8-；X代表氧、硫、-SO-或-SO2-；R4和R5分别独立地代表氢或C1-6烷基，或者与它们连接的氮或其他原子一起形成一个氮杂环烷基环或一个氧代取代的氮杂环烷基环；R6和R7分别独立地代表氢、C1-6烷基或氟；R8代表氢或C1-6烷基；m和n独立地代表从1和2中选择的整数；p独立地代表从0、1、2和3中选择的整数；或其药学上可接受的盐、溶剂或药学上可接受的衍生物。这些化合物在治疗中很有用，特别是作为抗精神病药物。
• Therapeutic compounds
  申请人：——

  公开号：US20030149024A1

  公开（公告）日：2003-08-07

  The present invention provides compounds of Formula I: 1 wherein X, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods as well as processes and intermediates useful for preparing compounds of Formula I.

  本发明提供了公式I的化合物：1其中X，R1，R2，R3，R4，R5和R6具有规范中定义的任何值，以及包含该化合物的制药组合物。该发明还提供了治疗方法以及用于制备公式I化合物的过程和中间体。
• Sulfonamide derivatives as antipsychotic agents
  申请人：Forbes Thomson Ian

  公开号：US20060063757A1

  公开（公告）日：2006-03-23

  The invention provides compounds of formula (I): wherein A and B represent the groups —(CH 2 ) m — and —(CH 2 ) n — respectively; R 1 represents hydrogen or C 1-6 alkyl; R 2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC -6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 5 R 6 , —SO 2 NR 5 R 6 , —(CH 2 )NR 5 R 6 , —(CH 2 ) p NR 5 COR 6 , optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R 3 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC 1-6 alkyl, trifluoromethyl, trifluoromethoxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) p OC 3-6 cycloalkyl, —COC 1-6 alkyl, —SO 2 C 1-6 alkyl, —SOC 1-6 alkyl, —S—C 1-6 alkyl, —CO 2 C 1-6 alkyl, —CO 2 NR 7 R 8 , —SO 2 NR 7 R 8 , —(CH 2 ) p NR 7 R 8 or —(CH 2 ) p NR 7 COR 8 ; R 4 represents hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 fluoroalkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO 2 CF 3 , —(CH 2 ) p C 3-6 cycloalkyl, —(CH 2 ) q OC 1-6 alkyl or —(CH 2 ) p OC 3-6 cycloalkyl; R 5 and R 6 each independently represent hydrogen, C 1-6 alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalkyl ring or an oxo-substituted azacycloalkyl ring; R 7 and R 8 each independently represent hydrogen or C 1-6 alkyl; m and n independently represent an integer selected from 1 and 2; p independently represents an integer selected from 0, 1, 2 and 3; q independently represents an integer selected from 1, 2 and 3; or a pharmaceutically acceptable salt or solvate thereof, with the proviso that the compounds 8-hydroxy-3-methyl-7-phenylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 8-hydroxy-7-4-(hydroxyphenyl)sulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine, 7-phenylsulfonyl- 1,2,3,4-tetrahydroisoquinoline and 7-phenylsulfonyl-1,2,3,4-tetrahydroisoquinoline hydrochloride are excluded. The compounds are useful in therapy, in particular as antipsychotic agents

  该发明提供了式（I）的化合物：其中A和B分别表示基团—（CH2）m—和—（CH2）n—；R1表示氢或C1-6烷基；R2表示氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR5R6、—SO2NR5R6、—（CH2）NR5R6、—（CH2）pNR5COR6、可选取代的芳香环、可选取代的杂芳环或可选取代的杂环基；R3表示氢、卤素、羟基、氰基、硝基、羟基C1-6烷基、三氟甲基、三氟甲氧基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、—（CH2）pC3-6环烷基、—（CH2）pOC3-6环烷基、—COC1-6烷基、—SO2C1-6烷基、—SOC1-6烷基、—S—C1-6烷基、—CO2C1-6烷基、—CO2NR7R8、—SO2NR7R8、—（CH2）pNR7R8或—（CH2）pNR7COR8；R4表示氢、羟基、C1-6烷基、C1-6烷氧基、C1-6氟烷氧基、三氟甲基、三氟甲氧基、卤素、—OSO2CF3、—（CH2）pC3-6环烷基、—（CH2）qOC1-6烷基或—（CH2）pOC3-6环烷基；R5和R6分别独立地表示氢、C1-6烷基或与它们所连接的氮或其他原子一起形成氮杂环烷基环或氧代取代的氮杂环烷基环；R7和R8分别独立地表示氢或C1-6烷基；m和n独立地表示选自1和2的整数；p独立地表示选自0、1、2和3的整数；q独立地表示选自1、2和3的整数；或其药学上可接受的盐或溶剂，但排除8-羟基-3-甲基-7-苯基磺酰基-2,3,4,5-四氢-1H-3-苯并噁唑、8-羟基-7-4-（羟基苯基）磺酰基-2,3,4,5-四氢-1H-3-苯并噁唑、7-苯基磺酰基-1,2,3,4-四氢异喹啉和7-苯基磺酰基-1,2,3,4-四氢异喹啉盐酸盐。这些化合物在治疗中有用，特别是作为抗精神病药物。
• Ion Channel Modulators & Uses Thereof
  申请人：Lawton Geoff

  公开号：US20090318423A1

  公开（公告）日：2009-12-24

  Compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH 2 or CH 2 CH 2 , R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is R5CO, R5SO 2 , R5R7NCO, R5R7NSO 2 , R5SO 2 NR7CO or CO 2 R8, Y is R6CO, R6SO 2 , R6R7NCO, R6R7NSO 2 , R6SO 2 NR7CO or CO 2 R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, are of use in the prophylaxis or treatment of diseases and conditions in which Kv1.x channels are involved, such as lower urinary tract disorders, cardiovascular diseases and pain.

  通式（1）及其药理学上可接受的盐和前药的化合物：公式（1）中，A和B是CH2或CH2CH2，R1是氢，烷基，环烷基，芳基，芳基烷基或杂芳基烷基，R2，R3和R4从氢，烷基，卤素，卤代烷基，烷氧基，烷氧羰基，羧基，羟基或氰基中选择；X是R5CO，R5SO2，R5R7NCO，R5R7NSO2，R5SO2NR7CO或CO2R8，Y是R6CO，R6SO2，R6R7NCO，R6R7NSO2，R6SO2NR7CO或CO2R8，R5和R6是氢，烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，R7是氢，烷基，芳基或芳基烷基，R8是烷基，芳基，芳基烷基，烷氧基烷基，杂芳基或杂芳基烷基，用于预防或治疗Kv1.x通道参与的疾病和病状，如下尿路疾病，心血管疾病和疼痛。
• Use of Ion Channel Modulators in the Prophylaxis and Treatment of Inflammatory and Immunological Diseases
  申请人：Lawton Geoff

  公开号：US20110130383A1

  公开（公告）日：2011-06-02

  Use of compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula (1) wherein A and B are CH 2 or CH 2 CH 2 , R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is R5CO, R5SO 2 , R5R7NCO, R5R7NSO 2 , R5SO 2 NR7CO or CO 2 R8, Y is R6CO, R6SO 2 , R6R7NCO, R6R7NSO 2 , R6SO 2 NR7CO or CO 2 R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, provided that when X is R5CO or R5SO 2 , then Y is not R6CO, R6SO 2 or R6R7NCO, in the manufacture of a medicament for the prophylaxis or treatment of inflammatory or immunological disease.

  通式（1）及其药理学上可接受的盐和前药的化合物的使用：式（1）其中A和B是CH2或CH2CH2，R1是氢，烷基，环烷基，芳基，芳基烷基或杂芳基烷基，R2、R3和R4从氢，烷基，卤素，卤代烷基，烷氧基，烷氧羰基，羧基，羟基或氰基中选择；X是R5CO，R5SO2，R5R7NCO，R5R7NSO2，R5SO2NR7CO或CO2R8，Y是R6CO，R6SO2，R6R7NCO，R6R7NSO2，R6SO2NR7CO或CO2R8，R5和R6是氢，烷基，芳基，芳基烷基，杂芳基或杂芳基烷基，R7是氢，烷基，芳基或芳基烷基，R8是烷基，芳基，芳基烷基，烷氧基烷基，杂芳基或杂芳基烷基，前提是当X是R5CO或R5SO2时，Y不是R6CO，R6SO2或R6R7NCO，用于预防或治疗炎症或免疫疾病的药物制剂的制造。